In a significant advancement for the field of precision oncology, a multidisciplinary team of investigators from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School of Public Health has identified the specific molecular mechanism by which certain gene rearrangements drive the progression of a rare and aggressive form of kidney cancer. The study, supported by the National Institutes of Health (NIH), reveals that proteins produced by these fusion genes aggregate into microscopic liquid droplets within the cell nucleus. These droplets, known as biomolecular condensates, act as command centers that abnormally activate genes responsible for tumor growth and metastasis.
The findings, published on April 22 in the journal Cell Reports, offer a potential roadmap for the development of targeted therapies for translocation renal cell carcinoma (tRCC). Currently, this specific subtype of kidney cancer lacks a standardized treatment protocol, often proving resistant to conventional therapies that are effective against more common forms of the disease. By identifying the physical state of these cancer-driving proteins, the researchers have opened the door to a new class of treatments designed to dissolve these liquid droplets and halt the progression of the malignancy.
The Challenge of Translocation Renal Cell Carcinoma
Translocation renal cell carcinoma is a distinct and rare subtype of kidney cancer characterized by chromosomal rearrangements. Unlike the more common clear cell renal cell carcinoma, which is often associated with mutations in the VHL gene, tRCC is defined by the fusion of the TFE3 gene with one of several partner genes. While tRCC accounts for approximately 1% to 5% of adult renal cell carcinomas, it is significantly more prevalent in pediatric and young adult populations, representing up to 40% of kidney cancers in children.
The disease is notoriously difficult to treat because it does not respond predictably to standard immunotherapy or tyrosine kinase inhibitors. For years, the scientific community has recognized that the fusion of TFE3 with other genes—such as PRCC, NONO, or SFPQ—was the primary driver of the disease. However, the precise "how" remained elusive. Scientists knew these fusion proteins were present in the nucleus, but the mechanism by which they hijacked the cell’s genetic machinery to promote uncontrolled growth was a missing piece of the puzzle.
"There are about 20 fusion partners of TFE3 in translocation renal cell carcinoma, but we mainly focused on the two most common ones, NONO and SFPQ, which together make up 40% of all TFE3 fusions," explained senior author Danfeng "Dani" Cai, Ph.D., an assistant professor of biochemistry and molecular biology at the Johns Hopkins Bloomberg School of Public Health.
The Discovery of Biomolecular Condensates
The breakthrough occurred when the research team utilized advanced imaging techniques to observe the behavior of TFE3 fusion proteins in real-time. By attaching fluorescent "glowing" tags to the fusion proteins within cells derived from kidney cancer patients, the researchers were able to visualize their distribution under a high-resolution microscope.
Instead of being evenly distributed throughout the nucleus, the fusion proteins clustered into distinct, shimmering dots. Dr. Cai’s laboratory, which specializes in the study of cellular "condensates," recognized these dots as liquid-liquid phase separations. Similar to how oil forms droplets in water, these proteins were separating themselves from the rest of the nuclear fluid to form concentrated "hubs" of activity.
These liquid condensates are not merely structural anomalies; they serve as functional compartments. The team observed that these droplets also recruited marker proteins typically associated with active gene transcription, as well as other proteins responsible for "turning on" genes. This suggested that the TFE3 fusion proteins were creating specialized environments to facilitate the high-speed activation of oncogenes—genes that transform healthy cells into cancerous ones.
Mapping the Chromatin Landscape
To understand how these droplets interact with the cell’s DNA, Dr. Cai collaborated with Eneda Toska, Ph.D., an assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. Together, they analyzed the "epigenetic landscape" of the cancer cells—the way DNA is packaged and modified to control gene expression.
In healthy cells, DNA is wrapped around proteins called histones, forming a structure known as chromatin. This structure is often compared to "beads on a string." When the string is tightly wound, genes are "silenced" or turned off because the cell’s machinery cannot reach them. When the string is loose, the genes are "open" and active.
"We found that these fusion proteins open and close different sites on the chromatin by making chemical modifications," Dr. Toska stated. "They bind, regulate, and redesign the chromosome landscape, interacting with target genes that promote cell proliferation and movement—functions that cancer needs to grow and spread."
The study revealed that the TFE3 fusion proteins have a significantly enhanced ability to remodel chromatin compared to the normal, full-length TFE3 protein. By forming condensates, the fusion proteins concentrate their power, allowing them to bind to DNA sites that are normally inaccessible, effectively rewriting the cell’s genetic program to favor malignancy.
Identifying the Coiled-Coil "Switch"
A critical component of the study involved deconstructing the TFE3 fusion proteins to identify which parts were essential for the formation of these liquid droplets. Using CRISPR gene editing and protein engineering, the researchers systematically removed different segments of the fusion proteins.
They discovered that a specific structural motif known as a "coiled-coil"—a shape where protein helices wrap around each other like the strands of a rope—was the key. This coiled-coil segment is located in the region where the TFE3 tail connects to its fusion partner (such as NONO or SFPQ).
When the researchers edited out this small coiled-coil segment, the TFE3 fusion proteins lost their ability to form liquid condensates. More importantly, without the droplets, the proteins were no longer able to activate the cancer-promoting genes. This finding confirmed that the physical state of the protein—its existence as a liquid droplet—is directly tied to its ability to cause cancer.
Chronology of the Research and Supporting Data
The journey toward this discovery involved several years of incremental findings and collaborative efforts:
- Initial Identification: Researchers identified TFE3 translocations in the early 2000s, establishing them as a unique diagnostic marker for tRCC.
- Focusing the Scope: Dr. Cai’s team began focusing on NONO-TFE3 and SFPQ-TFE3 fusions, which are particularly prevalent in aggressive cases.
- Imaging Breakthrough: The use of live-cell imaging and fluorescent tagging (circa 2021-2022) allowed for the first visualization of the "dots" in the nucleus.
- Chromatin Mapping: Integrating ChIP-seq and RNA-seq data allowed the team to correlate the location of the droplets with specific changes in the DNA landscape.
- Functional Validation: The final phase involved the "rescue" experiments, where removing the coiled-coil domain proved that the condensates were the functional drivers of the disease.
The data gathered during this study showed that the TFE3 fusion proteins were not just more active versions of normal proteins, but entirely new entities with "gain-of-function" properties. While full-length TFE3, NONO, and SFPQ all play roles in normal cellular machinery, their fusion creates a synergy that allows for a much more potent control over gene expression.
Implications for Future Therapies
The discovery that tRCC is driven by liquid condensates has profound implications for drug development. Traditional drug discovery often focuses on finding small molecules that fit into a "pocket" on a protein to inhibit its function. However, many transcription factors like TFE3 are considered "undruggable" because they lack these well-defined pockets.
The condensate model suggests a different approach: disrupting the physical environment that allows these proteins to cluster. "In future work, the research team hopes to identify other components in the liquid condensates that drive the cancer, which would allow them to screen for drugs or small molecules that can disrupt these structures," the investigators noted.
This strategy is not limited to kidney cancer. Dr. Cai pointed out that other malignancies, including Ewing sarcoma and certain types of leukemia, are also driven by fusion genes. "It’s possible that these fusion genes form similar droplets, or condensates, that regulate genes in these cancers and could react to similar treatment strategies," she said.
Broader Impact and Analysis
This research represents a shift in how scientists view the internal architecture of a cancer cell. The study of biomolecular condensates—often referred to as "membraneless organelles"—is one of the fastest-growing fields in cell biology. By proving that these structures are the engine behind tRCC, the Johns Hopkins team has validated the clinical relevance of this field.
For patients with rare cancers, who often feel left behind by the pace of "blockbuster" drug development, this study provides hope. Translocation renal cell carcinoma is a devastating diagnosis, particularly for young families. The identification of the coiled-coil domain as a "weak link" provides a specific target for future pharmaceutical intervention.
Furthermore, the study highlights the necessity of collaborative research. The partnership between the Bloomberg School of Public Health’s basic science expertise and the Kimmel Cancer Center’s clinical oncology focus was essential in bridging the gap between observing a "dot" under a microscope and understanding its impact on a patient’s chromatin.
Acknowledgments and Funding
The study was a collaborative effort involving researchers from multiple departments at Johns Hopkins and the National Cancer Institute. In addition to Drs. Cai and Toska, the team included Choon Leng So, Ye Jin Lee, Wanlu Chen, Binglin Huang, Emily De Sousa, Yangzhengyu Gao, Marie Elena Portuallo, Sumaiya Begum, Kasturee Jagirdar, Vito Rebecca, Hongkai Ji, Bujamin Vokshi, and W. Marston Linehan.
The research was supported by extensive funding from the National Institutes of Health (NIH), including grants from the National Institute of General Medical Sciences, the National Cancer Institute, and the National Human Genome Research Institute. Additional support was provided by the Department of Defense Kidney Cancer Idea Development Award, a Jayne Koskinas Ted Giovanis grant, and a Johns Hopkins Provost Catalyst Award.
Financial disclosures noted that Dr. Toska has received grants and consulting fees from AstraZeneca and Menarini, reflecting the ongoing interest of the pharmaceutical industry in the molecular pathways identified by this research.
As the scientific community moves forward, the focus will shift from the "what" of gene fusions to the "where" and "how" of their physical existence within the cell. This study stands as a cornerstone in that transition, moving the field closer to a day when rare kidney cancers can be treated with the same precision and success as more common ailments.
